INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is a complex and heterogeneous disease involved in multiple-stages and multiple-factors. The high rate of metastasis or post-operation recurrence and the low response rate to chemotherapy are responsible for poor prognosis of HCC patients \[[@R1]\]. Despite many risk factors account for the development of HCC, the growing evidence indicated that chronic and persistent infection with hepatitis B virus (HBV) is a major leading cause, particularly in China, where more than 80% of HCC cases has a history of HBV infection \[[@R1]\]. One of the open-reading frames encoded by the HBV genome, a multifunctional regulatory X protein (HBx), is believed to play vital roles in HBV-induced tumorigenesis \[[@R2]--[@R4]\]. As a trans-regulatory factor, HBx has promiscuous functions both *in vitro* and *in vivo*, including transactivation of cellular and viral promoters, regulation of signaling pathways, promotion of cell cycle progression, alteration of apoptosis, and damage of cellular DNA repair \[[@R2]\]. Therefore, HBx is likely to be involved in the several different steps of the development and progression of HCC \[[@R3]\]. In addition, immortalized hepatocytes stably transfected with the HBV genome form metastatic tumors upon inoculation in nude mice \[[@R4]\]. HBx mRNA selectively accumulates in HCCs from hepatitis B surface antigen-negative patients \[[@R5]\], suggesting a critical role for HBx in late events of the carcinoma development.

The random integration of HBV led to the truncation of viral proteins, particularly at the C-terminal ends of HBx \[[@R6]--[@R9]\]. These natural C-terminal truncated HBx (Ct-HBx), frequently expressed in HBV-associated HCCs, have been shown to abrogate the growth-suppressive effects induced by full-length HBx, increase the proliferation of neoplastic cell, and promote the transforming ability of hepatocytes \[[@R9]--[@R11]\]. Thus, Ct-HBx may play a important role in facilitating hepatocarcinogenesis via modifying biological functions of full-length HBx. Our and others groups have described that the full-length HBx participates in diverse process of HCC progression through inducing alternation of cellular morphology, disruption of adherens junction and epithelial-mesenchymal transition \[[@R10]--[@R14]\], but whether Ct-HBx play a role in HCC metastasis and the underlying mechanisms is little known. Although recent reports showed that Ct-HBx mutants can promote cell invasion and metastasis of HCC by up-regulating matrix metalloproteinase10 or down-regulating Wnt-5α \[[@R15], [@R16]\], in contrast to the full-length HBx, our understanding to functional contribution of C-terminal truncation of HBx during the progression of hepatocarcinigenesis is limited so far.

In the present study, we found that C-terminal truncation of HBx, particularly with the breakpoints at 124aa (HBxΔ31), is frequently expressed in HBV-related HCC and significantly associated with intrahepatic metastasis. We also show that ectopic expression of HBxΔ31 enhanced hepatoma cell invasion *in vitro* and metastasis *in vivo* by deregulating a set of putative metastasis-suppressors in HCC, in part through enhancing MAZ to its consensus sequence in the promoters. Notably, these HBxΔ31-repressed proteins were also lower expression in HCC tumors with Ct-HBx than the adjacent non-tumorous liver tissues and indicated poor prognosis in HCC patients. These results provide new insights into the molecular mechanisms of metastasis-suppressors in response to C-terminal truncation of HBx, revealing the importance of this novel HBxΔ31-driven metastatic molecular cascade during the metastasis of HBV-associated HCC.

RESULTS {#s2}
=======

Over-expression of Ct-HBx in HCC tissues is associated with intrahepatic metastasis {#s2_1}
-----------------------------------------------------------------------------------

To investigate whether the presence of natural Ct-HBx mutant is correlated with metastasis in HCC, we first examined HBx integrity (full-length or truncation) in the 102 HBV-positive HCC patients by PCR analysis using 5 pairs of PCR primers franking the different lengths of HBx sequence (Figure [1A](#F1){ref-type="fig"}). In all 102 HBV-positive patients, full-length HBx was frequently found in the non-tumorous tissues (92 of 102, 90.2%) but was rarely detected in HCC tissues (30 of 102, 29.4%; *p* \< 0.0001). In contrast, natural C-terminal truncation of HBx was more prevalent in HCC tumors (72 of 102, 70.6%) than in the adjacent non-tumorous liver tissues (46 of 102, 45%; *p =* 0.0032), indicating the presence of Ct-HBx is a frequent event in HCC (Figure [1A](#F1){ref-type="fig"}). Moreover, the HBx DNA breakpoints between 120aa to 130aa was the major form of truncation, being found in 45.8% (33/72) of the cases ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Interestingly, we identified two substantial-deletions in HBx gene from HCC tissues. The first deletion was at nucleotides (nt) 367-374 (codons 123-125) of HBx DNA. One nucleotide substitution produced a frame shift and a new stop codon (TAG) formation at the downstream (nt 381-383), leading to loss of 34aa and formation of 3 new amino acids at C-terminus. The second deletion was at nt 370-377 (codons 124-126) of HBx DNA. Two nucleotides substitution gave rise to a frame shift and a new stop codon (TAG) formation at the downstream (nt 381-383), resulting in loss of 33aa and formation of 2 new amino acids at C-terminus (Figure [1B](#F1){ref-type="fig"}). These two mutations generated HBx protein with 31aa shorter than full-length HBx, namely HBxΔ31.

![Detection of full-length and C-terminal truncated forms of HBx DNA in human HCC samples and mRNA in human hepatoma cell lines\
**A.** Representative results showed the presence of C-terminal truncated and full-length HBx DNA in HCC tumors (T) and their corresponding non-tumorous liver tissues (N). Case 135 had C-terminal truncated HBx DNA in tumor and full-length HBx in non-tumorous tissue. Case 289 showed the presence of full-length and C-terminal truncated HBx in both tumor and non-tumorous tissue, whereas case 305 was from an HBsAg-negative patient and showed no HBx DNA in both tumor and non-tumorous liver tissue. **B.** Sequencing analysis of PCR products showed the presence of two specific substantial deletions within HBx DNA from HCC tissues. On the upper panel: sequence alignment of full-length HBx DNA from a control sequence of HBV adw2 subtypes (GenBank accession number X02763) and case 135 with the deletion at nt 367-374 (codons 123-125), and case 210 with the deletion at nt 370-377 (codons 124-126). The 8-nucleotide deletions are shown as "////////". Lower letter represents the substantial nucleotide. On the lower panel: alignment of deduced amino acids (aa) at C-terminal end of HBx DNA from a control sequence of HBV adw2 (154aa) and HCC tissues of two patients (cases 135 and 210). Case 135: deletion at nt 367-374, frame shift and new stop codon formation, resulting in loss of 34aa and formation of 3 new amino acids. Case 210: deletion at nt 370-377, frame shift and new stop codon formation, resulting in loss of 33aa and formation of 2 new amino acids. The expected HBx protein of cases 135 and 210 each would be 31aa shorter than full-length HBx protein, denoted as HBxΔ31. Solid square represents new stop codon formed due to deletion and frame shift in HBx DNA. Lower letter represents the new amino acids. **C.** Binding locations of two PCR primer pairs targeting the full-length (F1-R5) and 3′-deleted (F1-R1) HBx gene. **D.** One representative example of HCC cases with HBx truncation in tumors, wherein the short HBx fragment were amplified from both tumor (T) and non-tumorous (N) tissues, but full-length HBx fragment was amplified only from adjacent non-tumorous liver tissues. β-actin was used as an internal control. **E.** RT-PCR analysis in HCC cell lines showed the presence of HBxΔ31 transcripts only in MHCC-LM3 cells, but not in other HCC cell lines or the immortalized normal liver cell lines.](oncotarget-07-55110-g001){#F1}

To further explore the functional significance of HBxΔ31 in development and progression of HCC, we analyzed expression of HBxΔ31 from DNA samples of the same 102 paired clinical HCC specimen using two pairs of PCR primers flanking different sequences of full-length HBx and HBxΔ31 (Figure [1C and 1D](#F1){ref-type="fig"}). As shown in Figure [1D](#F1){ref-type="fig"}, HBxΔ31 expression was frequently present in HCC tumors (78 of 102, 76.5%) compared to in the adjacent non-tumorous liver tissues (35 of 102, 34.3%; *p* \< 0.001) (Figure [1D](#F1){ref-type="fig"}). Next, we analyzed the correlation between HBxΔ31 expression and clinicopathological features of HBV-related HCC. We found that HBxΔ31 expression was significantly associated with intrahepatic metastasis of HCC (Table [1](#T1){ref-type="table"}), suggesting that the presence of HBxΔ31 in HCCs was involved in the progression of hepatocarcinogenesis.

###### Correlation between HBxΔ31, Maspin, RhoGDIα and CAPZB expression and clinicopathological features in human HCCs

  Characteristics           Tumor HBxΔ31 expression   P value         Tumor Maspin expression                    P value         Tumor RhoGDIα expression   P value                                      Tumor CAPZB expression   P value                                                                                    
  ------------------------- ------------------------- --------------- ------------------------------------------ --------------- -------------------------- -------------------------------------------- ------------------------ --------------- ------------------------------------------ --------------- --------------- ------------------------------------------
                            Negative (34)             Positive (68)                                              Negative (52)   Positive (50)                                                           Negative (55)            Positive (47)                                              Negative (62)   Positive (40)   
  Age (yr)                  50.5 (7.9)                51.4 (8.1)                                                 50.9 (8.1)      50.1 (8.5)                                                              51.8 (8.2)               50.5 (8.9)                                                 50.9 (8.4)      52.1 (8.1)      
  Gender                                                                                                                                                                                                                                                                                                                     
   Male                     25                        51              0.421                                      45              39                         0.642                                        39                       37              0.198                                      40              36              0.559
   Female                   10                        16                                                         12              6                                                                       16                       10                                                         18              8               
  Serum AFP                                                                                                                                                                                                                                                                                                                  
   \<20ng/mL                15                        27              0.887                                      37              26                         0.121                                        33                       30              0.195                                      35              26              0.87
   ≥20ng/mL                 21                        39                                                         25              14                                                                      20                       19                                                         20              21              
  Cirrhosis                                                                                                                                                                                                                                                                                                                  
   Absent                   15                        28              0.061                                      25              14                         0.78                                         22                       20              0.188                                      24              21              0.112
   Present                  20                        39                                                         33              30                                                                      30                       28                                                         31              26              
  Child-Pugh score                                                                                                                                                                                                                                                                                                           
   Class A                  27                        35              0.316                                      41              35                         0.12                                         40                       36              0.552                                      35              30              0.305
   Class B                  11                        29                                                         11              15                                                                      14                       12                                                         20              17              
  Tumor number                                                                                                                                                                                                                                                                                                               
   Single                   25                        37              0.306                                      38              36                         0.632                                        35                       36              0.145                                      40              32              0.411
   Multiple                 14                        26                                                         13              15                                                                      14                       17                                                         11              19              
  Tumor size                                                                                                                                                                                                                                                                                                                 
   \<5cm                    28                        39              0.205                                      42              37                         0.78                                         40                       32              O.558                                      44              30              0.553
   ≥5cm                     14                        31                                                         10              13                                                                      18                       12                                                         15              13              
  Tumor encapsulation                                                                                                                                                                                                                                                                                                        
   Absent                   10                        25              0.078                                      21              20                         0.065                                        19                       21              0.894                                      22              18              0.059
   Present                  27                        40                                                         34              27                                                                      33                       29                                                         35              27              
  Microvascular invasion                                                                                                                                                                                                                                                                                                     
   Absent                   23                        38              0.052                                      40              28                         0.001[\*](#tfn_001){ref-type="table-fn"}     32                       19              0.042[\*](#tfn_001){ref-type="table-fn"}   30              21              0.762
   Present                  12                        29                                                         22              12                                                                      20                       29                                                         25              26              
  Tumor differentiation                                                                                                                                                                                                                                                                                                      
   I-II                     21                        40              0.061                                      30              25                         0.049[\*](#tfn_001){ref-type="table-fn"}     31                       32              0.19                                       32              26              0.222
   III-IV                   11                        30                                                         19              28                                                                      21                       18                                                         20              24              
  Intrahepatic metastasis                                                                                                                                                                                                                                                                                                    
   Absent                   10                        31              0.001[\*](#tfn_001){ref-type="table-fn"}   40              19                         \<0.001[\*](#tfn_001){ref-type="table-fn"}   36                       17              0.021[\*](#tfn_001){ref-type="table-fn"}   32              15              0.012[\*](#tfn_001){ref-type="table-fn"}
   Present                  18                        43                                                         32              11                                                                      29                       20                                                         35              20              
  TNM stage                                                                                                                                                                                                                                                                                                                  
   I-II                     22                        46              0.059                                      36              28                         0.12                                         32                       34              0.106                                      30              35              0.114
   III-IV                   11                        25                                                         22              16                                                                      21                       13                                                         24              13              

*P*\<0.05

Detection of natural Ct-HBx in hepatoma cells {#s2_2}
---------------------------------------------

We also examined the expression of full-length HBx and its truncated mutant in the eight hepatoma cell lines and the two immortalized normal liver cell lines using two pairs of PCR primers targeting different sequences of full-length HBx and HBxΔ31 (Figure [1C](#F1){ref-type="fig"}). The results showed that the full-length HBx transcript was detected only in HepG2.2.15 cells, whereas Ct-HBx mRNA was found only in MHCC-LM3 cells (Figure [1E](#F1){ref-type="fig"}), indicating that natural truncated HBx with the lost of 31aa at the C-terminal end (HBxΔ31) is expressed in MHCC-LM3 cells with high metastatic potential.

Over-expression of Ct-HBx promotes invasion and metastasis of hepatoma cells *in vitro* and *in vivo* {#s2_3}
-----------------------------------------------------------------------------------------------------

We then established the stable cell lines, named HepG2-HBx and HepG2-HBxΔ31, after transfection of HA-tagged HBx or HBxΔ31 expressing vector. High expression of HBx gene was confirmed by Western blot analysis (Figure [2A](#F2){ref-type="fig"}). To determine the molecular mechanisms of the correlation between the presence of natural Ct-HBx and intrahepatic metastasis in HCCs, we analyzed the impact of full-length and HBxΔ31 on cell growth and cell migration and invasion ability in HCC cells. Transwell assays showed that both HepG2 cells expressing full-length and HBxΔ31 significantly enhanced cell migration and invasion ability compared to vector control cells. However, the number of migrated and invaded cells were more higher in HepG2 cells expressing HBxΔ31 than in HepG2 cells expressing full-length HBx (Figure [2C](#F2){ref-type="fig"}), suggesting that over-expression of HBxΔ31 promotes HCC cell migration and invasion. On the other hand, we also observed that ectopic expression of HBxΔ31 in MIHA hepatocytes lost the growth-suppressive effect of full-length HBx ([Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}), but over-expression of HBxΔ31 did not change significantly the growth rates of HepG2 cells (Figure [2B](#F2){ref-type="fig"}). These results indicated that deletion of 31aa from C-terminus of HBx facilitates the cell migratory and invasive capacities but not affect on the cell growth at same situation in HCC. To excluding possible roles of cell lines, we investigated this effect of HBxΔ31 in Huh7 cells, and observed consistent with the effect of HBxΔ31 on the migration and invasion ability of HepG2 cells ([Supplementary Figure S2B, S2C](#SD1){ref-type="supplementary-material"}).

![Over-expression of HBxΔ31 in HepG2 enhanced cell invasion and tumor metastasis\
**A.** Schematic diagram showing the different constructs of HBx used in this study. Western blot analysis of HBx expression in HepG2 cells stably transfected with HA-tagged HBx- or HBxΔ31-expressing plasmid and control vector pRc/CMV. β-actin was used as loading control. 1) Parental HepG2, 2) pRc/CMV, 3) Full-length HBx, 4) HBxΔ31. **B.** The growth rates of HBxΔ31- expressing cells was significantly increased compared to vector control, but had no effect on that of full-length HBx-expressing cells. **C.** The number of migrated or invaded cells was significantly increased in HBxΔ31-expressing cells, as compared to full-length HBx-expressing or vector control cells. Bars represent the numbers of migrated or invaded cells per field under 100 magnification. **D, E.** *In vivo* metastasis assay. (D) Representative images of livers from the different groups is shown. Black arrows indicate the intrahepatic metastatic tumors. (E) The number of metastatic nodules in the liver were counted and analyzed with Student\'s *t*-test (six mice per group). Results are derived from triplicate independent experiments (±SD).](oncotarget-07-55110-g002){#F2}

To further determine the role of HBxΔ31 in HCC metastasis *in vivo*, we established a animal model of HCC metastasis by implanting HCC cells expressing various forms of HBx into the livers of nude mice. Eight weeks after orthotopic implantation, the number of intrahepatic metastatic nodules was more over 2.0-fold increase in the mouse implanted with HepG2 cells expressing HBxΔ31 than in the mouse with HepG2 cells expressing full-length HBx (Figure [2D](#F2){ref-type="fig"}). Histological analysis further confirmed that over-expression of HBxΔ31 in HepG2 cells significantly enhanced the intrahepatic metastasis, as compared to both full-length HBx counterpart and vector control (51.2% vs. 30.8%, 51.2% vs. 18.2%, respectively) (Figure [2E](#F2){ref-type="fig"}). The results was consistently with over-expression of HBxΔ31 in Huh7 cells increased intrahepatic metastasis ([Supplementary Figure S2D](#SD1){ref-type="supplementary-material"}).

Deregulation of metastasis-related proteins by Ct-HBx in hepatoma cells {#s2_4}
-----------------------------------------------------------------------

To investigate the machanistic basis of the distinctive effect of HBxΔ31 and full-length HBx on HCC cell invasion and metastasis, we performed proteomic analysis. Six proteins were displayed significantly differential expression (\>2-fold change) in HepG2-HBxΔ31 compared to HepG2-HBx (Figure [3A](#F3){ref-type="fig"}), including up-regulated three proteins (MRPL12, RanBP1 and HSPB1), and down-regulated 3 proteins (Maspin, RhoGDIα and CAPZB) (Figure [3B](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Furthermore, Western blot analysis further validated the proteomic findings (Figure [3C](#F3){ref-type="fig"}). Intriguingly, some of HBxΔ31-repressed proteins, for example Maspin and RhoGDIα are reported to have anti-metastatic functions \[[@R23], [@R24]\], indicating a potential molecular mechanism that HBxΔ31 promotes HCC progression by reducing the expression of a subset of metastasis suppressors.

![HBxΔ31 deregulates the metastasis-related proteins in HepG2 cells\
**A.** Representative silver-stained 2-DE profiles are shown from full-length HBx-expressing cells (HepG2-HBx, left) and HBxΔ31-expressing cells (HepG2-HBxΔ31, right). Proteins (400 μg) were focused over an IPG pH gradient of 4-7 and then separated by 10% acrylamide SDS-PAGE. Blue arrows indicate proteins that were deregulated proteins with at least 2-fold difference in HepG2-HBxΔ31 cells. Protein spots detected only in HepG2-HBxΔ31 cells are circled in red. **B.** Confirmation of the differentially-expressed proteins by Western blot analysis. Six proteins with divergent expression patterns between HepG2-HBx and HepG2-HBxΔ31 are shown. Comparing to full-length HBx, HBxΔ31 significantly up-regulated MRPL12, HSPB1 and RanBP1, whereas down-regulated Maspin, RhoGDIα and CAPZB in HepG2 cells. β-actin was used as an internal control. **C.** Fold changes of the differentially-expressed protein levels in HBx-expressing cell lines after normalization with β-actin are shown. Results are derived from triplicate independent experiments (±SD).](oncotarget-07-55110-g003){#F3}

###### Identification of the differentially expressed proteins in HepG2-HBx and HepG2-HBxΔ31 cells

  Spot No.   Protein   Protein name                                        Mr(Da)   PI    Coverage   Score   Ratio[\*\*](#tfn_003){ref-type="table-fn"}   Functions
  ---------- --------- --------------------------------------------------- -------- ----- ---------- ------- -------------------------------------------- ---------------------------------------
  2          P52815    39S ribosomal protein L12, mitochondrial (MRPL12)   21,348   5.2   36         105     2.2                                          Cell growth
  3          P47756    F-actin-capping protein subunit beta (CAPZB)        31,350   5.6   52         192     −3.1                                         Cell motility, migration and invasion
  5          P04792    Heat shock protein beta-1 (HSPB1)                   22,783   6.6   41         160     2.4                                          Cell growth, apoptosis and migration
  6          P43487    Ran-specific GTPase-activating protein (RanBP1)     23,310   6.2   47         255     2.0                                          Cell growth
  8          P52565    Rho GDP-dissociation inhibitor 1 (RhoGDIα)          23,207   5.3   38         156     −2.2                                         Cell motility, migration and invasion
  9          P36952    Maspin (Serpin B5)                                  42,100   5.5   37         278     −2.6                                         Cell growth and metastasis

Accession number of the UniProt database

average ratio of HepG2-HBxΔ31 group/HepG2-HBx group.

Maspin, RhoGDIα and CAPZB are transcriptionally repressed by Ct-HBx in HCC cells {#s2_5}
--------------------------------------------------------------------------------

To query whether HBxΔ31 could repress Maspin, RhoGDIα and CAPZB transcriptions in hepatoma cells, we performed real-time-PCR analysis. As a result, we found that over-expression of HBxΔ31 decreased the mRNA levels of Maspin, RhoGDIα and CAPZB in MIHA and HepG2 cells compared with full-length HBx and control vector (Figure [4A](#F4){ref-type="fig"} and [Supplementary Figure S3A](#SD1){ref-type="supplementary-material"}). Moreover, the protein levels of Maspin, RhoGDIα and CAPZB, as determined by Western blotting, were similarly reduced by HBxΔ31 compared with full-length HBx and control vector in MIHA and HepG2 cells (Figure [4A](#F4){ref-type="fig"} and [Supplementary Figure S3B](#SD1){ref-type="supplementary-material"}). In addition, luciferase reporter assay showed that promoter activities of Maspin, RhoGDIα and CAPZB were significantly decreased by HBxΔ31 in MIHA and HepG2 cells compared with full-length HBx counterpart and control vector (Figure [4B](#F4){ref-type="fig"} and [Supplementary Figure S3C](#SD1){ref-type="supplementary-material"}). Therefore, we conclude that Ct-HBx, rather than the full-length HBx counterpart, represses Maspin, RhoGDIα and CAPZB transcriptions by modulating their promoter activity.

![HBxΔ31 transcriptionally represses the RhoGDIα and CAPZB expressions through enhancing MAZ binding to the promoter\
**A.** Real-time PCR and Western blot analysis showing that HBxΔ31 repressed RhoGDIα and CAPZB expressions in MHIA and HepG2 cells. **B.** Dual luciferase report assay showing that HBxΔ31 repressed the RhoGDIα and CAPZB promoters. **C.** The sequence analysis demonstrated that the HBxΔ31 repressive element located between nt.-744 to −460 of the RhoGDIα promoter, while between nt. −680 to −440 of the CAPZB promoter. On the left panel, the schematic representation of the reporter gene constructs is shown; on the right panel, bars represent the relative promoter activity in each of the transfected cells. **D.** On the left panel, analysis of the cis-regulatory elements between nt. −744 to −460 in the RhoGDIα promoter revealed 2 Sp1 binding sites (GGGCGGG) and 3 MAZ binding sites (CCCTCCC), whereas between nt. −680 to −440 in the CAPZB promoter exhibited 1 Sp1 binding sites and 3 MAZ binding sites. On the right panel, MAZ sites in the RhoGDIα or CAPZB promoter was essential for HBxΔ31-induced RhoGDIα or CAPZB trans-suppression. Mutations in the Sp1 sites had no effect on the RhoGDIα and CAPZB promoter activities, whereas mutations in the MAZ sites significantly enhanced their promoter activities regulated by HBxΔ31. **E.** Coimmunoprecipitation assay showed a direct binding of HBxΔ31, but not full-length HBx, to MAZ in HCC cells. The arrow marks the location of a background band. **F.** EMSA assay confirmed enhancement of the DNA binding activity of MAZ to the RhoGDIα promoter by HBxΔ31.](oncotarget-07-55110-g004){#F4}

Lys-123 residue in HBxΔ31 is essential for the down-regulation of RhoGDIα and CAPZB expressions {#s2_6}
-----------------------------------------------------------------------------------------------

To determine the region of HBxΔ31 involved in the suppression of RhoGDIα and CAPZB, we compared the suppression ability of two different Ct-HBx mutants, HBxΔ31 and hbxΔ31. HBxΔ31 is a HBx natural variant with 31aa truncated and accompanied with formation of 3 new amino acids at C-terminus, whereas hbxΔ31 is generated by a HBx artificial mutant with 31aa deleted at C-terminus from pRc/HBx (HBV adw2 subtype). As shown in [Supplementary Figure S4A and S4B](#SD1){ref-type="supplementary-material"}, two mutants generated completely diverse effects on the RhoGDIα and CAPZB expressions. HBxΔ31, but not hbxΔ31, was found to produce remarkable suppression effect on the RhoGDIα and CAPZB expressions. To further determine the critical amino acid residue in HBxΔ31 for this effect, we investigated whether the double substitution E121V and L123G was required for the distinct modulation of RhoGDIα and CAPZB expressions. Using three artificial HBxΔ31 variants with the substituted amino acid residues at 121st and/or 123th position in HBxΔ31, we found that only HBxΔ31 mutants changing codon 123 of the X protein from Lys to Glu (hbxΔ31L123G and hbxΔ31E121V/L123G) could effectively inhibit RhoGDIα and CAPZB expressions, up to the level obtained with HBxΔ31 ([Supplementary Figure S4A](#SD1){ref-type="supplementary-material"}), suggesting that Lys-123 is essential for the repressions of RhoGDIα and CAPZB.

MAZ is critical for Ct-HBx-induced RhoGDIα and CAPZB trans-suppression {#s2_7}
----------------------------------------------------------------------

To define the roles of the *cis*-regulatory elements of the RhoGDIα and CAPZB promoters in response to HBxΔ31 regulation, we made a series of deleted variants of the RhoGDIα and CAPZB promoters and individually co-transfected with pCMV-HBxΔ31 or control vector into HepG2 cells (Figure [4C](#F4){ref-type="fig"}). The results of RhoGDIα deletion mutants showed HBxΔ31 still has repression on nt −1038 to −744, but lost its repression ability on nt −460, indicating that the HBxΔ31 repressive element localized between nt −744 and −460 of RhoGDIα promoter (Figure [4C](#F4){ref-type="fig"}). On the other hand, the results of CAPZB deletion mutants showed HBxΔ31 still has repression on nt −920 to −680, but lost its repression ability on nt −440, suggesting that the HBxΔ31 repressive element localized between nt −680 and −440 of CAPZB promoter (Figure [4C](#F4){ref-type="fig"}).

Using the Transcription Element Search Software program, analysis of the cis-regulatory elements between nt −744 to −460 of RhoGDIα promoter revealed 2 Sp1 binding sites (GGGCGGG) and 3 MAZ binding sites (CCCTCCC), while between nt −680 to −440 of CAPZB promoter had 1 Sp1 sites and 3 MAZ sites (Figure [4D](#F4){ref-type="fig"}). These HBxΔ31 repressive elements were changed by site-directed mutagenesis. The results showed that the mutation in Sp1 sites had no effect on the RhoGDIα or CAPZB promoter activity, whereas the mutation in MAZ sites significantly increased HBxΔ31-regulated RhoGDIα and CAPZB promoter activities (Figure [4D](#F4){ref-type="fig"}), indicating that the MAZ sites was required for their promoter inactivation regulated by HBxΔ31.

To determine whether HBxΔ31 enhanced transcriptional repression of MAZ, we examined interaction between MAZ and HBxΔ31 by coimmunoprecipitation experiment. Cells were co-transfected with MAZ and HA-tagged HBx or HBxΔ31 expressing plasmids, and then HBx were immunoprecipitated with anti-HA antibody. MAZ was detected in the immunoprecipitates by Western blot with anti-MAZ antibody. Reversely, HBx or HBxΔ31 was detected in immunoprecipitation with anti-MAZ antibody subjected to Western blot with anti-HA antibody. The results conformed that HBxΔ31, but not HBx, could directly associate with MAZ (Figure [4E](#F4){ref-type="fig"}).

To further determine the effect of HBxΔ31 on the recruitment of MAZ to the RhoGDIα and CAPZB promoters, we preformed Gel shift assay using an biotin-labeled oligonucleotide containing the MAZ binding sequence derived from the the RhoGDIα promoter (−252 to −262) was used as the probe. As shown in Figure [4F](#F4){ref-type="fig"}, enhanced binding to the wild-type oligonucleotide was observed in nuclear extracts from HBxΔ31-expressing HepG2 cells as compared with those from vector controls. We then analyzed the specificity of MAZ binding activity. The results showed that increased binding did not occur in the nuclear extract of HBxΔ31 incubated with the mutant oligonucleotides. The unlabeled wild-type oligonucleotides were able to compete with the labeled wild-type oligonucleotide, while the mutant oligonucleotides had no effect on the binding of the MAZ-HBxΔ31 complex to the labeled wild-type oligonucleotide, indicating HBxΔ31 represses RhoGDIα or CAPZB expression by enhancing MAZ binding to its consensus sequence.

Maspin, RhoGDIα and CAPZB function to counteract HBxΔ31-induced invasion and metastasis of HCC cells {#s2_8}
----------------------------------------------------------------------------------------------------

To address the role of Maspin, RhoGDIα and CAPZB proteins in HCC metastasis, we abolished endogenous expression of Maspin, RhoGDIα or CAPZB using a short hairpin RNA (shRNA) in HepG2 cells, respectively. Inhibition of Maspin, RhoGDIα or CAPZB expression increased cell migratory and invasive activity (Figure [5A](#F5){ref-type="fig"}), which was similar to the phenotype induced by HBxΔ31 (Figure [2C](#F2){ref-type="fig"} and [5B](#F5){ref-type="fig"}). In contrast, HepG2 cells with ectopic expression of Maspin, RhoGDIα or CAPZB showed a 75% to 79% reduction of cell migration and invasion compared to vector control cells (Figure [5B](#F5){ref-type="fig"}).

![Maspin, RhoGDIα and CAPZB exert metastasis-inhibitory function in HBxΔ31-induced HCC cell invasion and metastasis\
**A.** The shRNA-mediated silencing of Maspin, RhoGDIα and CAPZB promoted HCC cell migration and invasion. HepG2 and Huh7 cells were infected with lentivirus-expressing Maspin shRNA (LV-shMaspin), RhoGDIα shRNA (LV-shRhoGDIα), CAPZB shRNA (LV-shCAPZB), or control shRNA (LV-shcontrol). On the upper panel, *In vitro* migration and invasion assays. On the lower panel, Western blot. **B.** Ectopic expressions of Maspin, RhoGDIα and CAPZB inhibited HBxΔ31-induced cell migration and invasion. HepG2 cells were co-transfected with lentivirus-expressing Maspin (LV-Maspin), RhoGDIα (LV-RhoGDIα), CAPZB (LV-CAPZB) or control (LV-control) and HBxΔ31-expressing plasmid or control vector. **C.** Suppression of Maspin, RhoGDIα and CAPZB expressions by HBxΔ31 increased the incidence of pulmonary and intrahepatic metastasis *in vivo*. The numbers of metastatic nodules in the lungs and liver in different groups of nude mice were counted and analyzed with Student\'s *t*-test (five mice per group). Results are derived from triplicate independent experiments (±SD).](oncotarget-07-55110-g005){#F5}

To investigate whether Maspin, RhoGDIα and CAPZB exert the similar function in HBxΔ31-mediated HCC metastasis, we over-expressed HBxΔ31 with or without Maspin, RhoGDIα or CAPZB in HepG2 cells, and examined their metastasis both *in vitro* and *in vivo*. The results showed that HBxΔ31 enhanced both cell migration and invasion in HepG2 cells. Notably, HBxΔ31-induced cell migration and invasion were reduced upon co-expression of Maspin, RhoGDIα or CAPZB (Figure [5B](#F5){ref-type="fig"}). Concordantly, *in vivo* metastasis assay demonstrated pulmonary and intrahepatic metastasis nodules formed from HepG2-HBxΔ31 cells were significantly increased compared to that of control cells, whereas the numbers of metastasis-nodules formation of HepG2-HBxΔ31+Maspin, HepG2-HBxΔ31+RhoGDIα and HepG2-HBxΔ31+CAPZB cells were similar to that of control cells (Figure [5C](#F5){ref-type="fig"}). Consistent results were also observed in Huh7 cells. As shown in [Supplementary Figure S5](#SD1){ref-type="supplementary-material"}, down-regulation of Maspin, RhoGDIα and CAPZB expressions increased cell invasion and metastasis in Huh7 cells. Overall, these data demonstrate that Maspin, RhoGDIα and CAPZB function as the putative metastasis-suppressors in HCC and that are indeed the functional target for HBxΔ31.

Ablation of Maspin, RhoGDIα and CAPZB correlate with C-terminal HBx truncation in HCC tissues {#s2_9}
---------------------------------------------------------------------------------------------

To determine the clinical significance of Maspin, RhoGDIα and CAPZB down-regulation by HBxΔ31, we first examined the expression levels of Maspin, RhoGDIα and CAPZB in a cohort of 102 HBV-related HCC and their matching non-tumorous tissues using immunohistochemistry assay. The levels of Maspin, RhoGDIα and CAPZB were significantly lower in 60.8% (62 of 102), 68.6% (70 of 102) and 70.6% (72 of 102) of HCC tissues, respectively than the high basal levels of the matching non-tumorous tissues (Figure [6A](#F6){ref-type="fig"}) (*p* \< 0.05). We then analyzed the relationship between the loss of Maspin, RhoGDIα and CAPZB expressions and clinical-pathological features. The results showed that Maspin, RhoGDIα and CAPZB down-regulation was correlated with multiple malignant characteristics, including microvascular invasion, malignant differentiation, and intrahepatic metastasis in HBV-associated HCC patients (Table [1](#T1){ref-type="table"}). Kaplan-Meier analysis indicated that patients with low Maspin, RhoGDIα and CAPZB expressions had short overall survival than those with high Maspin, RhoGDIα and CAPZB expressions (Figure [6B](#F6){ref-type="fig"}), suggesting that reduced expressions of Maspin, RhoGDIα and CAPZB was implied in poor prognosis of HCC patients.

![Down-regulation of Maspin, RhoGDIα and CAPZB is correlated with C-terminal truncated HBx in HCC samples\
**A.** Immunohistochemical staining of Maspin, RhoGDIα and CAPZB in HCC and adjacent non-tumorous tissue. (b) staining of Maspin in HCC-1, score 2; (a) non-tumorous tissue matched with HCC-1, score 4; (d) staining of RhoGDIα in HCC-2, score 2; (c) non-tumorous tissue matched with HCC-2, score 4; (f) staining of CAPZB in HCC-3, score 2; (e) non-tumorous tissue matched with HCC-3, score 4. The cases of each score were counted and are shown in the table. Statistical analysis was performed with Student\'s *t*-test. HCC, n = 102. For all three proteins, immunostaining was observed in the cytoplasm. Scale bar, 50μm. **B.** Kaplan-Meier analysis of the correlation between Maspin, RhoGDIα and CAPZB expressions and the overall survival of HBV-associated HCC patients. **C.** Comparison of Maspin, RhoGDIα and CAPZB mRNA expressions in 40 selected paired tumor (T) and non-tumorous (N) tissues which are only positive for HBxΔ31, using *PNN* as internal control. The bars (shown in log scale) illustrate the relative Maspin, RhoGDIα and CAPZB mRNA levels (T/N) in individual tissue pairs, of which negative and positive values respectively indicate down- and up-regulation of Maspin, RhoGDIα and CAPZB in HCCs. The differences of T and N groups are statistically significant (*p* \< 0.05). **D.** A schematic diagram of the role of Maspin, RhoGDIα and CAPZB in the progression of HBV-associated HCC is shown.](oncotarget-07-55110-g006){#F6}

To further explore a link between HBxΔ31 expression and Maspin, RhoGDIα and CAPZB repressions in the same clinical specimens, we examined the mRNA levels of Maspin, RhoGDIα and CAPZB in 40 specific HCC specimens with HBxΔ31-positive by real-time PCR. The levels of Maspin, RhoGDIα and CAPZB were remarkably reduced in 70% (28 of 40), 72.5% (29 of 40) and 75% (30 of 40) of HCC tissues, respectively, as compared to their matching non-tumorous tissues (\>1.5-fold change in 32 of 40 (80%), 31 of 40 (77.5%) and 33 of 40 (82.5%) of samples, respectively) (*p* \< 0.05, Figure [6C](#F6){ref-type="fig"}), indicating that these metastasis-suppressors were at least partially suppressed by C-terminal truncation of HBx in HCC tissues.

DISCUSSION {#s3}
==========

Previous studies have shown that HBx gene is frequent and spontaneous mutation in human HCC and leads to C-terminally truncated HBx (Ct-HBx) protein \[[@R6]--[@R9]\]. Nevertheless, such deletion of HBx is more often in tumors rather than their matching non-tumorous liver tissues. In this study, 70.6% (72 of 102) of HBV-associated HCC tissues contained Ct-HBx DNA and breakpoints between 120aa to 130aa was the major form of deletion (45.8% of the 72 cases) (Figure [1](#F1){ref-type="fig"} and [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Our result was consistent with that of a recent study showing that 79% of HCC from China had Ct-HBx transcript in tumor tissues \[[@R10]\]. These evidences indicate that C-terminally truncated mutation of HBx is frequent event in HCC. Interestingly, we identified two specific 8-nucleotides deleted mutations (codons 123-125 or 124-126) in HBx gene. All were accompanied with formation of a new stop codon and generated 31aa truncated at C-terminus, donated as HBxΔ31. It is noted that these truncation were different from the mutations previous reported within codons 128-134 of HBx sequence in HCC tissues \[[@R8], [@R9], [@R17]\]. Furthermore, HBxΔ31 was often over-expressed in HCC tissues, as compared with adjacent non-tumorous tissues and significantly correlated with its intrahepatic metastases (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}), indicating that the presence of Ct-HBx has clinical significance.

We then attempted to illustrate the underlying mechanism of the correlation between the presence of HBxΔ31 and intrahepatic metastases in HCC by assessing cell invasion and metastasis. We showed that HBxΔ31 significantly enhanced HCC cell invasive and migratory activity compared with full-length HBx or control vector (Figure [2C](#F2){ref-type="fig"} and [Supplementary Figure S2C](#SD1){ref-type="supplementary-material"}). Moreover, the role of HBxΔ31 in cell invasion and migration is also evident in mouse hepatocytes, which increased intrahepatic metastatic nodules formation *in vivo* (Figure [2D](#F2){ref-type="fig"} and [Supplementary Figure S2D](#SD1){ref-type="supplementary-material"}), consistently demonstrating that HBxΔ31 play a significant role in promoting cell invasion and metastasis in HCC. In addition, we found that HBxΔ31 lost the growth-suppression effect induced of full-length HBx only in normal liver cell lines. However, the correlation between the over-expression of HBxΔ31 and cell growth did not been found in HCC cells (Figure [2B](#F2){ref-type="fig"} and [Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}), suggesting that full-length HBx may be important in relation to anti-proliferation function, whereas its truncation with 31aa lost at C-terminal end mainly services as pro-metastasis effect in HCC cells. Further studies will be needed to confirm this notion.

To further explore the molecular basis of the divergent effect of full-length HBx and HBxΔ31 on HCC cell invasion and metastasis, we compared the proteomic profiles in HepG2 cells expressing full-length HBx and HBxΔ31. We identified that HBxΔ31 distinctively regulated 6 metastasis-related proteins, including three up-regulated and 3 down-regulated proteins, compared with full-length HBx (Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). For example, HBxΔ31-up-regulated protein, soluble heat shock protein B1 (HSBP1), regulates VEGF-mediated angiogenesis through their direct interaction \[[@R18]\]. Regulation of HSBP1 on NF-κB pathway activation is involved in metastatic HCC cells apoptosis \[[@R19]\]. In contrast, HBxΔ31-down-regulated proteins, such as mammary serine protease inhibitor (Maspin) and Rho GDP dissociation inhibitor α (RhoGDIα), reveal anti-metastatic functions in various cancer types including HCC \[[@R20],[@R21]\]. We further confirmed the metastasis-inhibitory effects of Maspin, RhoGDIα and CAPZB in hepatoma cells. These findings provide potential mechanism to insight into how Ct-HBx promotes cells invasion and metastasis in HCC.

During natural process of HBV infection, several mutations tend to be accumulated in the HBx gene coding sequence, which can impact its biological function and subsequent tumorigenic potential. Previous study demonstrated that some point mutations in HBx gene, such as the double substitution K130M and V131I, generated completely distinct impact on regulation of E-cadherin expression and cell migration \[[@R11]\]. In this study, we found that HBxΔ31, rather than full-length HBx, repressed Maspin, RhoGDIα and CAPZB expressions at transcription initial steps by inducing their promoter inactivation. Further analysis showed that HBxΔ31 coding region at 120-125aa residues produces a double substitution E121V to L123G mutations in contrast to full-length HBx gene (Figure [4](#F4){ref-type="fig"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). Interestingly, only the HBxΔ31 variants containing Lys-123 instead of Glu-123 (L123G) effectively reduced RhoGDIα and CAPZB expressions ([Supplementary Figure S4A-S4B](#SD1){ref-type="supplementary-material"}). Lys-123 has been shown to localize in the trans-activation domain of HBx \[[@R4]\]. Therefore, we speculate that Lys-123-containing HBxΔ31 may more effectively regulate transcription suppressor MAZ expression, resulting in RhoGDIα and CAPZB promoter inactivation. Further investigation should be warranted.

HBx is essential for trans-activation of HBV and host cell gene. Despite having no binding to DNA directly, HBx can deregulate cellular gene expression by interacting with transcription regulators in the nucleus \[[@R2]--[@R4], [@R22]\]. Previous reports showed that full-length HBx can transcriptionally suppress a subset of important tumor-related genes through enhancing the promoters binding to transcription suppressors like E2F1, SMAD4, YY1 and MAZ \[[@R23]--[@R25]\]. In this report, deletion and mutation analysis of the RhoGDIα and CAPZB promoters revealed that the MAZ binding sites is critical for HBxΔ31-mediated RhoGDIα and CAPZB suppression (Figure [4C and 4D](#F4){ref-type="fig"}). However, HBxΔ31 did not affect binding of Sp1 to its consensus sequence in the RhoGDIα or CAPZB promoters, while the RhoGDIα or CAPZB promoter activities were increased when the MAZ binding sites were mutated in HBxΔ31-expressing cells, suggesting that MAZ is a suppressor of the RhoGDIα or CAPZB promoter. Coimmunoprecipitation experiment showed that HBxΔ31, but not full-length HBx, physical associated with MAZ (Figure [4E](#F4){ref-type="fig"}). EMSA assays further confirmed that HBxΔ31 enhanced the DNA binding activity of MAZ to the RhoGDIα and CAPZB promoters (Figure [4F](#F4){ref-type="fig"}). Thus, HBxΔ31 repressed RhoGDIα and CAPZB expressions by enhancing the binding of MAZ to the RhoGDIα and CAPZB promoters through its physical association with MAZ. The results was consistent with previous report, which HBx with point mutation at C-terminus acts as a transcriptional co-repressor on telomerase promoter by enhance MAZ binding to the promoter \[[@R24]\], suggesting that C-terminus of HBx may play a critical role in trans-suppression of the specific cancer-related gene. In addition, we identified that amino acids 104 to 124 domain of HBxΔ31 is required for the binding to MAZ to the promoter region of RhoGDIα and CAPZB ([Supplementary Figure S4C-S4E](#SD1){ref-type="supplementary-material"}). These findings indicated that Ct-HBx-dependent ablation of RhoGDIα and CAPZB through MAZ may be one of major reasons underlying the decreased expressions of RhoGDIα and CAPZB in hepatoma cells.

Interestingly, besides HBxΔ31 interacting with MAZ resulting in RhoGDIα down-regulation, over-expressed miR-151 can repress RhoGDIα expression and facilitate tumor cell migration and spreading in HCC \[[@R28]\]. It has been reported that CpG site promoter methylation led to Maspin down-regulation in tumors \[[@R29], [@R30]\]. Our unpublished data also revealed that HBxΔ31 represses Maspin expression by inducing promoter hypermethylation through activation of DNA methyltransferase 1 and in turn promotes cell invasion and metastasis in HCC. Thus, in addition to Ct-HBx, other mechanism might be involved in suppression of Maspin, RhoGDIα or CAPZB in HCC cells. Further studies are warranted.

The loss of expression or function of metastasis-suppressor genes is a critical inducer for triggering a series of metastatic events initiate \[[@R32]\]. According to previous studies, Maspin, RhoGDIα and CAPZB are often deregulated in many malignancies and significantly correlated with metastasis, recurrence and prognosis \[[@R31], [@R37]--[@R39]\]. Functional studies further delineated that Maspin, RhoGDIα and CAPZB play important roles during tumor metastasis by influencing cell morphology, adhesion junctions and migration ability of tumor cells \[[@R32], [@R33], [@R36]\]. However, the functional link between Maspin, RhoGDIα along with CAPZB and HBV-related HCC metastasis has not been explored so far. In this report, we found that Maspin, RhoGDIα and CAPZB were reduced expressions in two HCC cell lines and human HCC tissues (Figure [2](#F2){ref-type="fig"} and Figure [6](#F6){ref-type="fig"}). Subsequent functional analyses further demonstrated that Maspin, RhoGDIα and CAPZB act to impede the invasion and metastasis of HCC cells *in vitro* and *in vivo* (Figure [5](#F5){ref-type="fig"} and [Supplementary Figure S5](#SD1){ref-type="supplementary-material"}). Moreover, we demonstrated that Maspin, RhoGDIα and CAPZB expressions were significantly lower in HCC tissues with C-terminal truncation of HBx than the matching non-tumorous liver tissues (Figure [6](#F6){ref-type="fig"}) and associated with metastatic characteristics and poor prognosis in HCC patients (Table [1](#T1){ref-type="table"} and Figure [6](#F6){ref-type="fig"}). These findings establish a metastasis-suppressive role of Maspin, RhoGDIα and CAPZB in HCC, and indicate that down-regulation of Maspin, RhoGDIα and CAPZB is vital for Ct-HBx-mediated progression of hepatocarcinogensis.

Maspin is a member of the serine protease inhibitor (serpin) superfamily and displays tumor-suppressing activity by controlling cell migration, proliferation, apoptosis, and adhesion, whose down-regulation was significantly correlated with poor prognosis of patients in several types of tumors \[[@R30], [@R32]\]. Recent report showed that down-regulation of Maspin by miRNA-7/21/107 confers HBx-mediated aggressiveness in HCC \[[@R37]\]. In our present study, we verified that HBxΔ31-dependent suppression of Maspin by inducing inactivation of its promoter resulted in the enhancement of invasion and metastasis of HCC cells.

Another important metastasis-suppressor transcriptionally repressed by Ct-HBx is RhoGDIα, a regulator of Rho activity, controls on Rho family GTPases, including Rac1, Cdc42 and Rho GTPases activation. RhoGDIα/Rac1 signal pathway plays an essential role in regulating cell morphology, adhesion, and motility. The aberrant expression of RhoGDIα was related to tumor metastasis and poor clinical outcomes in aggressive cancers \[[@R21], [@R33], [@R34]\]. In this study, we found that ectopic expression of RhoGDIα reduced HBxΔ31-induced cell invasion and metastasis. Moreover, RhoGDIα was a direct transcriptional and functional target of HBxΔ31. These data strongly suggested that RhoGDIα contribute to HBxΔ31-induced HCC progression.

Cell migration often requires profound changes in cellular architecture, with protrusion of different structures such as pseudopodia, filopodia, or lamellipodia \[[@R35], [@R36]\]. F-actin capping protein (CP), a heterodimer composed of α and β subunits, inhibits actin filaments elongation by binding to barbed ends of growing actin filaments, which is a critical step for creating actin architecture of lamellipodia and consequential cell protrusion and motility \[[@R37]--[@R39]\]. Reports on the role of CP in cancer are rare thus far. A recent study showed that CPα1 subunit (CAPZA1) down-regulation in gastric cancer was associated with poor prognosis and with increased cancer cell migration and invasion \[[@R40]\]. In this report, we show for the first time that CPβ subunit (CAPZB) was repressed by Ct-HBx in HCC. Functional assays revealed that the forced expression of CAPZB resulted in a significant reduction for HBxΔ31-expressing HepG2 cell migration and invasion. These findings demonstrated that CAPZB functions to counteract HBxΔ31-induced cell invasion and metastasis. Taken together, Ct-HBx may alter cell migratory and invasive ability and subsequently promote HCC metastasis through repressing metastasis suppressors and interfering their corresponding gene-network.

In conclusion, our data show that C-terminal truncation of HBx, particularly with breakpoint at 124 amino acids (HBxΔ31), can significantly promote HCC cell invasion and metastasis *in vitro* and *in vivo*. Meanwhile, HBxΔ31 exerts this function via specifically suppressing a set of metastasis-suppressors (Maspin, RhoGDIα and CAPZB) expressions, in part, by enhancing their promoter binding to transcription suppressor MAZ through its physical association with MAZ. This newly identified HBxΔ31/Maspin, RhoGDIα or CAPZB module provides a new insight into an understanding of the progression of hepatocarcinogenesis, especially invasion and metastasis, and may facilitate the development of potential therapeutics against HBV-associated HCC.

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

One hundred two pairs of human HCCs and their corresponding non-tumorous liver tissues from chronic HBV-infection patients with liver resection for HCC between 2005 and 2012 at the First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China), were randomly selected for study. These 102 patients had positive serum hepatitis B surface antigen (HBsAg) status. Patients\' ages ranged from 39 to 72 years; 76 were male and 26 female. All specimens were snap-frozen in liquid nitrogen and kept at −80°C. Frozen sections were cut from non-tumorous liver and tumor blocks separately and stained for histological examination to ensure a homogenous cell population of tissues. The accompanied intrahepatic metastases were observed through both naked eyes and microscope. Follow-up data were summarized at the end of December 2012 with a median follow-up of 44 months (range 6-88 months). Human tissue samples were collected with written consent of the patients and prior approval from Clinical Research Ethics Committee of Guangzhou Medical University. The clinical characteristics of the patients are listed in Table [1](#T1){ref-type="table"}.

Cell lines {#s4_2}
----------

HCC cell lines including HepG2, HepG2.2.15, Hep3B, Huh7, SMMC7721, MHCC97L, MHCC97H and MHCCLM3 and two immortalized normal liver cell lines LO2 and MIHA were purchased from the American Type Culture Collection (ATCC). All cells were maintained in high-glucose cultured in Dulbecco\'s modified Eagle\'s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (HyClone).

Plasmids {#s4_3}
--------

Full-length HBx DNA (adw2 subtype; NCBI-X02763) was amplified from HBx/pcDNA3.1^+^ plasmid and subcloned into HA/pCMV6-AN vectors. HBx truncation mutant with 31aa delated at C-terminus (denoted HBxΔ31) was made and subcloned into HA/pCMV6-AN vectors. Wild-type RhoGDIα (−1038 to +24), CAPZB (−920 to +20) and Maspin (−467 to +50) promoters were amplified from healthy human liver DNA, respectively. The mutants with mutations at the putative Sp1 or MAZ transcription factor binding sites on the RhoGDIα or CAPZB promoters were subcloned into pGL3-Basic vector. MAZ-expressing plasmid was made by introducing the corresponding complementary DNAs (cDNAs) into pRc/CMV vector. Lentiviral vectors encoding short hairpin RNAs (shRNAs) were generated with the use of PLKO.1-TRC (Addegene) and were designated as LV-shRhoGDIα, LV-shCAPZB, LV-shMaspin and LV-shcontrol, respectively. Lentiviral vectors encoding human RhoGDIα, CAPZB and Maspin gene were constructed in FUW-teto (Addegene), designated as LV-RhoGDIα, LV-CAPZB and LV-Maspin. The empty vector was used as negative control, designated as LV-control. All primers are shown in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

Establishment of HBx-expressing cells {#s4_4}
-------------------------------------

HepG2 and Huh7 cells were transfected with HA-tagged HBx and HBxΔ31 expressing plasmids or control vector using Lipofectamine 2000 (Invitrogen), according to manufacture\'s protocol. HBx-expressing cells were selected with G418 at 700 μg/mL for 14 days. The individual clones were confirmed to express HBx by western blot analysis using anti-HA antibody.

Two-dimensional electrophoresis {#s4_5}
-------------------------------

Prior to two-dimensional electrophoresis, the protein samples were purified using a 2D Clean-Up kit (GE healthcare) according to the manufacturer\'s instructions. Differentially expressed proteins were identified using two-dimensional gel electrophoresis and mass spectrometry. Two-dimensional gel electrophoresis was performed using immobiline strips (p*I* range, 3-10; GE Healthcare) with proteins being separated according to charge and subsequently molecular weight. The gels were then silver stained in order to visualize proteins and the differentially expressed spots were identified by MALDIPMF mass spectrometry.

Western blot analysis {#s4_6}
---------------------

Cells were lyzed in sodium dodecyl sulfate (SDS) containing buffer and equal amounts of protein were separated in SDS/polyacrylamide gel electrophoresis gel for western blotting analysis. Immunodetection was performed using anti-HA, anti-MAZ and anti-β-actin (Santa Cruz), **anti**-HSPB1 and anti-CAPZB (LSBio), anti-Maspin and anti-RhoGDIα (Abcam), anti-MRPL12 and anti-RanBP1(Cell Signaling Technology).

Luciferase reporter assay {#s4_7}
-------------------------

HepG2 cells were transfected with different combinations of plasmids using FuGENE 6 reagent (Roche), according to the manufacturer\'s protocol. Plasmids used included HA/pCMV6-AN vector containing various forms of HBx, RhoGDIα-WT/pGL3-Basic, RhoGDIα-MAZ-Mut/pGL3-Basic and CAPZB-WT/pGL3-Basic, CAPZB-MAZ-Mut/pGL3-Basic reporter constructs, and an internal control (pRL-SV40). The total amount of expression vectors was equalized with the empty vector. Twenty four hours after transfection, luciferase and Renilla luciferase activities were measured by the Dual Luciferase Reporter assay system (Promega), according to the manufacturer\'s protocol. Transfection efficiency was normalized with the Renilla luciferase activity. Experiments were done thrice independently.

Coimmunoprecipitation assay {#s4_8}
---------------------------

Cells were cotransfected with pCMV-MAZ and either pCMV-HA/HBx or pCMV-HA/HBxΔ31. Forty-eight hours after transfection, cells were lysed in TBS containing 0.5% NP-40. The cell debris was removed by a brief centrifugation in a microcentrifuge. The supernatant was then immunoprecipitated with anti-HA antibody. The immunocomplex precipitated with Pansorbin was then analyzed by Western blotting with anti-MAZ primary antibody. Alternatively, the cell lysates were first immunoprecipitated with anti-MAZ antibody, followed by Western blotting with the anti-HA primary antibody.

Electrophoretic mobility shift assay (EMSA) {#s4_9}
-------------------------------------------

The preparation of the HepG2 cells nuclear extracts and the gel shift assay were described previously \[[@R15]\]. The biotin end-labeled double-strand oligonucleotide probe used for the gel shift contained the sequence 5′-AGCCCTCCCCA-3′ (−252 to −262 in RhoGDIα promoter) or a mutant oligonucleotide 5′-AGCCCTATACA-3′ covering the putative MAZ-binding sites at the promoter region was employed for standard PCR measurement in the EMSA assay. EMSA was performed using the LightShift® Chemiluminescent EMSA Kit (Pierce) according to the manufacturer\'s protocol.

*In vitro* migration and invasion assay {#s4_10}
---------------------------------------

For the migration assays, 5×10^4^ cells were placed into the top chamber of each insert. For the invasion assay, 1×10^5^ cells were added to the upper chamber of each insert coated with 150 μg of Matrigel. After several hours of incubation at 37°C, cells that had migrated or invaded were fixed and stained in dye solution containing 0.1% crystal violet and 20% methanol. The cells that had migrated or invaded were counted and imaged using an inverted microscope (Olympus).

*In vivo* metastasis assay {#s4_11}
--------------------------

BALB/C nude mice (6-8 weeks) were housed under standard conditions and cared for according to the institutional guidelines for animal care. All animal experiments were approved by the Guangdong Province Medical Experimental Animal Care Commission. For *in vivo* metastasis assays, 4×10^6^ cells in phosphate-buffered saline to a volume equivalent to 8% of the total body weight of each animal were injected subcutaneously into the flanks of nude mice. After 4 weeks, the subcutaneous tumors were removed and diced into 1 mm^3^ cubes, which were then implanted in the left lobes of the livers of the nude mice (six per group). After 8 weeks, mice were sacrificed, and their livers and lungs were dissected and prepared for standard histological examination.

Statistical analysis {#s4_12}
--------------------

For clinic-pathological correlation analysis, Fisher\'s exact test was used for analysis of categorical data. For *in vitro* cell migration and invasion assay and reporter assay, the Student *t* test was used for continuous data. Two-sided *P* values less than 0.05 were considered as statistically significant.
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